510(k) Report

510(k) · Cleared

Cleared

Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx, Cefaly Dual Connected - OTC, Cefaly Dual Connected - Rx

K212071510(k) TraditionalCleared Dec 13, 2022529-day reviewClass II21 CFR 882.5891

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Cefaly Technology · PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine

Cleared on Dec 13, 2022 as substantially equivalent to K173006 (Cefaly Technology, 2017) and 1 other predicate after a 529-day review. Its family tree reaches back 5 generations to 2014. 2 later devices descend from it.

Decided
Dec 13, 2022
Review
529 days
Class
Class II
Product code
PCC
Recalls
None
Predicates
2

Its longest line of descent runs back 5 generations to DEN120019 (2014). 2 later devices descend from it, 1 citing it directly.

  1. Root · 5 generations backDEN120019 CefalyStx-Med Sprl · 2014
  2. 4 generations backK160237 CefalyCefaly Technology · 2016
  3. 3 generations backK171446 Cefaly AcuteCefaly Technology · 2017
  4. 2 generations backK173006 Cefaly DualCefaly Technology · 2017
  5. 1 generation backK201895 Cefaly DualCefaly Technology · 2020
  6. This deviceK212071 Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID…Cefaly Technology · 2022
  7. Descendant · cites it directly · 1 of its ownK234029 CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology · 2024
  8. Descendant · 2 generations on · 0 of its ownK254216 Enso for MigraineHinge Health, Inc. · 2026

Most influential descendants

Showing 2 of 2 · See all
  • K234029CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology · 2024 · cites it directly1descendant
  • K254216Enso for MigraineHinge Health, Inc. · 2026 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−5DEN120019CefalyStx-Med Sprl2014—
−4K160237CefalyCefaly Technology2016—
−3K171446Cefaly AcuteCefaly Technology2017—
−2K173006Cefaly DualCefaly Technology2017—
−1K201895Cefaly DualCefaly Technology2020—
0 (this device)K212071Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx…Cefaly Technology2022—
+1K234029CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology2024—
+2K254216Enso for MigraineHinge Health, Inc.2026—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202410
202610
FIG. 1 — Lineage of K212071, 2014–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PCC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PCC device

  1. #1 K201895 Cefaly Dualscore 16.0 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K173006Cefaly Dual
Summary page 5
…Product 510(k) Subject Device Number CEFALY Cefaly® Dual K173006 ● Cefaly® Dual Technology Connected Rx,…
Cefaly Technology2017—
*K201895Cefaly Dual
Summary page 5
…Enhanced with RFID Rx CEFALY Cefaly® Dual K201895 ● Cefaly® Dual Technology Connected…
Cefaly Technology2020—

Also cleared against K173006: 2 other devices →

What descends from it? (2)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K234029CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology20241

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 8 years and passes through 2 companies; a new generation was cleared every 2.0 years on median.
  • None of the 5 ancestors has a recall.
  • Of its descendants, K234029 (Cefaly Technology, 2024) has gone furthest, with 1 descendant of its own.
  • 2 other devices also cite its predicate K173006.

How does its category compare?

All PCC devices

PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.

FDA decisions per year · PCC

5in 2024

2014: 12016: 12017: 22018: 12019: 12020: 12021: 42022: 12024: 52026 (partial year): 1
2007high 5 (2024) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PCC

211in 2024

2021: 88 days median2024: 211 days median
2007high 211 (2024) · low 88 (2021)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PCC

No recall names PCC since 2007.

Adverse event reports per year · PCC

2in 2025

2014: 22016: 22017: 22019: 22020: 12021: 72023: 22024: 62025: 2
2007high 7 (2021) · low 0 (2007)2025

MAUDE reports naming product code PCC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20141—02
20150—00
20161—02
20172—02
20181—00
20191—02
20201—01
202148807
20221—00
20230—02
2024521106
20250—02
20261—0—

What is it indicated for?

Cefaly Dual Connected - OTC and Cefaly Dual Enhanced with RFID - OTC are indicated for:

1. Acute treatment of migraine with or without aura in patients 18 years of age or older

2. Preventative treatment of migraine in patients 18 years of age or older

Cefaly Dual Connected - Rx and Cefaly Dual Enhanced With RFID - Rx are indicated for:

1. Acute treatment of migraine with or without aura in patients 18 years of age or older

2. Prophylactic treatment of migraine in patients 18 years of age or older

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K212071: Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx, Cefaly Dual Connected - OTC, Cefaly Dual Connected - Rx.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K212071

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026